The U.S. Food and Drug Administration (FDA) has officially granted modified risk tobacco product (MRTP) orders for 20 ZYN nicotine pouch products manufactured by Swedish Match USA. 

The decision marks a major moment for the nicotine pouch category and further reinforces the growing role smoke-free nicotine alternatives are playing in the tobacco harm reduction conversation. 

Under the authorization, the approved ZYN products may now legally be marketed with the following FDA-authorized claim: 

“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” 

For adult nicotine consumers, it is one of the strongest public acknowledgments yet from the FDA that non-combustible nicotine products can present significantly lower risks compared to smoking cigarettes. 

Which ZYN Flavors Were Authorized? 

The FDA’s modified risk granted orders apply to the following ZYN flavors, each authorized in both 3mg and 6mg nicotine strengths: 

• ZYN Chill  
• ZYN Cinnamon  
• ZYN Citrus  
• ZYN Coffee  
• ZYN Cool Mint  
• ZYN Menthol  
• ZYN Peppermint  
• ZYN Smooth  
• ZYN Spearmint  
• ZYN Wintergreen  

These products were originally authorized through the PMTA pathway in January 2025, but this latest action now allows Swedish Match to communicate specific reduced-risk information directly to adult consumers. 

What Is an MRTP Authorization? 

An MRTP order is different from a standard PMTA authorization. 

While PMTA authorization simply allows a product to be legally sold in the United States, the MRTP pathway allows manufacturers to market products with FDA-reviewed reduced-risk claims when supported by substantial scientific evidence. 

To receive this authorization, the FDA evaluated: 

• Toxicology and health risk data  
• Consumer understanding of the claim  
• Population-level impact  
• Potential youth uptake concerns  
• Behavioral studies and scientific literature  

According to the FDA, Swedish Match demonstrated that the modified risk claim is scientifically accurate, understandable to consumers, and beneficial to public health overall. 

Why This Matters for Nicotine Pouches 

The nicotine pouch category has exploded in popularity over the past several years as more adult smokers and nicotine users look for smoke-free alternatives. 

Unlike cigarettes, nicotine pouches do not involve combustion, smoke, ash, or vapor. That distinction is critical because combustion is responsible for the overwhelming majority of smoking-related disease. 

FDA’s authorization does not mean nicotine pouches are risk-free. The agency continues to emphasize that no tobacco product is completely safe and that non-users should not start using nicotine products. 

However, the FDA also acknowledged that completely switching from cigarettes to authorized nicotine pouches may reduce exposure to many harmful chemicals associated with smoking. 

That is a significant statement for both consumers and the broader tobacco harm reduction debate. 

A Big Step for Tobacco Harm Reduction 

For years, public health experts and harm reduction advocates have argued that adult smokers deserve access to accurate information about lower-risk nicotine alternatives. 

This authorization reflects a continued shift toward recognizing the continuum of risk between combustible cigarettes and smoke-free nicotine products. 

It also sets an important precedent for future nicotine pouch applications and other reduced-risk products seeking FDA authorization. 

What Happens Next? 

As part of the authorization, Swedish Match must continue conducting postmarket surveillance and studies to monitor: 

Consumer understanding of the claim  

• Usage patterns  
• Population-level effects  
• Youth uptake trends  

The modified risk orders expire in five years unless renewed by the FDA. 

The agency also retains the authority to withdraw the authorization if future evidence shows the products no longer benefit public health overall. 

Looking to the Future 

FDA’s modified risk authorization for 20 ZYN nicotine pouch products is one of the most significant nicotine pouch regulatory developments to date. 

While the FDA continues maintaining strict oversight of tobacco and nicotine products, this decision further confirms that smoke-free alternatives backed by strong scientific evidence can receive authorization to communicate reduced-risk information to adult consumers. 

For adult smokers exploring alternatives to cigarettes, it is another sign that the conversation around nicotine harm reduction continues to evolve.